1RK Stock Overview
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Inhibrx, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$31.80 |
52 Week High | US$38.00 |
52 Week Low | US$13.40 |
Beta | 2.91 |
1 Month Change | -1.24% |
3 Month Change | -8.62% |
1 Year Change | 72.83% |
3 Year Change | 82.76% |
5 Year Change | n/a |
Change since IPO | 17.78% |
Recent News & Updates
Recent updates
Shareholder Returns
1RK | DE Biotechs | DE Market | |
---|---|---|---|
7D | -0.6% | 0.8% | 1.2% |
1Y | 72.8% | -24.4% | 2.0% |
Return vs Industry: 1RK exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 1RK exceeded the German Market which returned 2% over the past year.
Price Volatility
1RK volatility | |
---|---|
1RK Average Weekly Movement | 3.2% |
Biotechs Industry Average Movement | 4.9% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1RK has not had significant price volatility in the past 3 months.
Volatility Over Time: 1RK's weekly volatility has decreased from 8% to 3% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 169 | Mark Lappe | inhibrx.com |
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company’s therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.
Inhibrx, Inc. Fundamentals Summary
1RK fundamental statistics | |
---|---|
Market cap | €1.51b |
Earnings (TTM) | -€225.62m |
Revenue (TTM) | €1.68m |
896.8x
P/S Ratio-6.7x
P/E RatioIs 1RK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1RK income statement (TTM) | |
---|---|
Revenue | US$1.80m |
Cost of Revenue | US$191.64m |
Gross Profit | -US$189.84m |
Other Expenses | US$51.52m |
Earnings | -US$241.36m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -5.09 |
Gross Margin | -10,546.67% |
Net Profit Margin | -13,408.94% |
Debt/Equity Ratio | 475.8% |
How did 1RK perform over the long term?
See historical performance and comparison